Relation of p53 Codon 72 Polymorphism with Breast Cancer Risk in DPR Korea Women
Abstract
Background: The p53 codon 72 polymorphism (rs1042522) is a single-nucleotide polymorphism (SNP) in exon 4 of p53 gene, resulting in the expression of either arginine (Arg), which encodes CGC, or proline (Pro), which encodes CCC. The p53 codon 72 polymorphism have been implicated as a risk factor for various cancers including breast cancer. We have investigated the association of the Arg/Pro polymorphism at codon 72 of p53 gene with breast cancer risk in women from DPR Korea. Methods: Tumor tissue samples from 97 women with primary breast carcinoma and radix pili tissue samples from 96 healthy females were collected and then analyzed through polymerase chain reaction (PCR). Results: The proportion of the polymorphic forms of SNP72 in DPR Korea breast cancer patients were Arg/Arg (RR), 17.5%; Pro/Pro (PP), 1.0%; and Arg/Pro (RP), 81.4%. The frequencies of these forms in healthy females were 30.2%, 3.1% and 66.7%, respectively. This indicated that Arg/Pro and Pro/Pro has higher risk of breast cancer than Arg/Arg (Odds ratio=2.0, 95% Confidential Interval=1.0~4.0, P=0.039). But no correlation between the genotype distribution and clinicopathological features of breast cancer was observed. Conclusion: In dominant genetic model of Pro allele, a statistically significant association was found between the p53 codon 72 polymorphism and breast cancer risk. These results suggested that Pro72 allele was associated with higher risk for breast cancer patients. Women with Pro72 allele have increased risk of developing breast cancer.
Keywords: Breast cancer, breast cancer risk, risk factor, p53 codon 72 (Arg72Pro) polymorphism
Cite this Article
Tae-Yong Jon, Hui-Myong Pak, Chong-Won Ri, Chong-Kwon Ri, Un-Rim Sim. Relation of p53 Codon 72 Polymorphism with Breast Cancer Risk in DPR Korea Women. Research & Reviews: A Journal of Bioinformatics. 2020; 7(1): 23–30p.
Downloads
Additional Files
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |